TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05384171

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Measurement-Based Transition Assistance (MBTA)
Description: Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Measurement-Based Transition Assistance (MBTA)
Description: Measurement-Based Transition Assistance (MBTA) asks Veterans about their well-being and then provides Veterans with individualized feedback on areas in which they would benefit from additional support with regard to their health, vocational, financial, and social circumstances, along with personalized recommendations for relevant programs, services, and supports.
Study: NCT06355102

Intervention type: OTHER
Intervention: Conventional treatment and care
Description: Conventional treatment and care

Intervention type: OTHER
Intervention: Conventional treatment and care
Description: Conventional treatment and care

Intervention type: OTHER
Intervention: Conventional treatment and care
Description: Conventional treatment and care
Study: NCT06397417

Intervention type: OTHER
Intervention: Data collection
Description: The data from hospital treatment will be used for research as well as subsequently, that is to say after discharge from the intensive care units, medical reports and correspondence with the attending physician will be used for the study.
Study: NCT05781945

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy
Description: standard therapy for sars-cov-2
Study: NCT05856526

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spesolimab - solution for injection
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab - solution for injection
Description: Solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching to spesolimab - solution for injection
Description: Solution for injection
Study: NCT04883645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% Cream
Description: Imiquimod as a 5% cream is being used to treat several skin cancers, including malignant melanoma, basal cell carcinoma (BCC) and SCC. With respect to SCC treatment, it has been demonstrated that imiquimod stimulates tumor destruction by recruiting T cells (cells in the immune system) from blood and by inhibiting tonic anti-inflammatory signals within the tumor. The patient will be instructed to apply imiquimod cream, 7 nights a week for 4 weeks to the oral tumor at bedtime.
Study: NCT04739761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan
Description: Participants will receive T-DXd administered using an IV bag containing 5% (w/v) dextrose injection infusion solution.
Study: NCT04799301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with no soda
Description: Weight-maintaining diet without soda, with all carbohydrates originating from sources other than corn and sugar cane

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with 50% of carb intake from soda
Description: Weight-maintaining diet with 50% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet with 20% of carb intake from soda
Description: Weight-maintaining diet with 20% of carbohydrates provided as soda, and all other carbohydrates originating from sources other than corn and sugar cane
Study: NCT06293469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Accelerated Flap Coverage Surgery
Description: Timing of the flap surgery is with a goal of 72 hours from injury

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Flap Timing
Description: Timing of the flap surgery is the standard of care flap timing for the participating institution.
Study: NCT05907096

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARGX-117
Description: Intravenous administration of ARGX-117

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous administration of placebo
Study: NCT05054790

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neo-Bladder Construct
Description: Subjects will undergo an open full thickness bladder biopsy from which autologous urinary bladder smooth muscle and urothelial cells will be procured and expanded ex vivo. After approximately 5 - 7 weeks, expanded cells will be seeded on a biodegradable scaffold to produce the neo-bladder construct that will be surgically implanted onto an opened native bladder during an augmentation cystoplasty.
Study: NCT05949801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neucardin
Description: 10 days IV infusion of 0.6 ug/kg/day
Study: NCT06141395

Intervention type: DIAGNOSTIC_TEST
Intervention: NGS-based assay for bacterial identification
Description: A total volume of 26ml of whole blood will be sampled from each enrolled patient for three consecutive days. This will be used for Standard-of-Care (SoC) culture and Next Generation Sequencing (NGS), for identification of circulating microorganisms.
Study: NCT05949801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 days IV infusion of 0 ug/kg/day
Study: NCT05394597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repellent lotion
Description: lotion of the repellent active ingredient IR3535

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repellent Wipe
Description: wipe of the repellent active ingredient IR3535
Study: NCT05257499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On line debriefing
Description: Online Debriefing in the Simulation Sessions of the Helping Babies Breathe Course
Study: NCT05413889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Epic 30-day unplanned readmission risk score
Description: If a patient is identified as having a high risk of readmission defined as readmission risk \>20%, a link to transitional and supportive care services (TSC) will be appear in the story board.
Study: NCT06244875

Intervention type: OTHER
Intervention: Sampling
Description: Blood and cerebrospinal fluid sampling during the diagnostic visit
Study: NCT05403359

Intervention type: DRUG
Intervention: Steroids
Description: Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28.

Intervention type: DRUG
Intervention: Steroids
Description: Description of the intervention in each of the work packages:~* WP1A admission: Steroid dose \>6mg/day dexamethasone equivalent will be compared to control (steroid = 6mg/day dexamethasone or equivalent steroid).~* WP1B late: After 10 days of dexamethasone therapy patients are stratified in high-dose steroids (\> 6 mg dexamethasone or equivalent steroid) or no steroids up to day 28.~* WP2 ICU admission: High-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) compared to dexamethasone 6 mg up to 72 hours after admission~* WP3 ICU late: After dexamethasone 6 mg for 10 days patients are stratified in high-dose steroids (dexamethasone \>6 mg daily or equivalent corticosteroids) or no steroids up to day 28.
Study: NCT05783531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VMood
Description: VMood is a digital mental health intervention adapted from an evidence-based in-person intervention. It uses supported self-management approaches, consisting of bibliotherapy (the Antidepressant Skills Workbook) and supportive coaching from a social worker that are provided via the smartphone app. The individual is supported in the use of the skills over the course of three months. The skills in the workbook are grounded in principles of Cognitive Behavioural Therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced treatment as usual
Description: Participants in the control arm will receive enhanced treatment as usual in the form of usual care from primary care centres and a brief introduction to depression video through the VMood app.
Study: NCT06287944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Actinium Ac 225-DOTA-Daratumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiography
Study: NCT05413317

Intervention type: OTHER
Intervention: Color Doppler Ultrasound
Description: Comparison with conventional diagnosis strategy including a clinical probability score, D-dimers and chest imaging.
Study: NCT06287944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo SCT
Study: NCT05643001

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In-patient and out-patient electronic health record alert
Description: Electronic health record best practice alert which suggests measurement of LDL and HbA1c (in-patient) and referrals to sleep study and audiology (out-patient)
Study: NCT06505369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab will be administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered by oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be administered by oral route

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered by SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered by SC injection
Study: NCT05663710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu girentuximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu girentuximab
Description: Given by IV (vein)
Study: NCT05743270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified herpes simplex type 1 virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RP3
Description: Genetically modified herpes simplex type 1 virus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCRT(concurrent chemoradiation therapy)
Description: CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
Study: NCT05663710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu girentuximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO
Study: NCT06287944

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Indium In 111-DOTA-Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo nuclear scan
Study: NCT05386862

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduce THC Use
Description: Reducing THC concentrations and increasing CBD to reduce PTSD symptom severity
Study: NCT05894980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS stimulating left DLPFC
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the left DLPFC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS stimulating right OFC
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 2 mA) applied to the right OFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: 20 active tDCS sessions (4 sessions/day for 5 days, 30 min each, 0 mA) applied to the left DLPFC
Study: NCT05663710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by PO
Study: NCT06287944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given sirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given tacrolimus

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Marrow and Lymphoid Irradiation
Description: Undergo TMLI
Study: NCT05397041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMB-101
Description: Participants will receive one of several different oral doses of BMB-101 once or twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched Placebo
Study: NCT05663710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV (vein)
Study: NCT05224024

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retzius-repairing robot-assisted radical prostatectomy
Description: Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
Study: NCT04368494

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home based exercise
Description: Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
Study: NCT05663710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ArabinoFuranosylGuanine [18F]F-AraG
Description: Given by IV (vein)
Study: NCT05548712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Electromagnetic Field
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulse Electromagnetic Field
Description: Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
Study: NCT06452641

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jones technique
Description: Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
Study: NCT05600088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoTherapy System (CTS)
Description: local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
Study: NCT06267768

Intervention type: DIAGNOSTIC_TEST
Intervention: Various intensities of inspiratory muscle training
Description: Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.

Intervention type: DIAGNOSTIC_TEST
Intervention: Various intensities of inspiratory muscle training
Description: Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
Study: NCT06452641

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-friction massage
Description: Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
Study: NCT05743270

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCRT(concurrent chemoradiation therapy)
Description: CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: chemotherapeutic agents
Study: NCT05224024

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Retzius-repairing robot-assisted radical prostatectomy
Description: Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
Study: NCT06444984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Trial
Description: Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed Trial
Description: Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
Study: NCT05854446

Intervention type: OTHER
Intervention: Survey
Description: In this survey, The experts will be asked open-ended questions based on the literature research and patient surveys carried out by the researchers in the first round to identify key themes related to myofascial pain syndrome, including the disease burden, patient journey, and unmet diagnosis and treatment needs. In subsequent rounds, the experts will rate the importance of each theme and provide additional feedback.
Study: NCT05532501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Oxytocin
Description: Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
Study: NCT04751994

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron drops/Ferrous sulphate
Description: participant will consume daily drops of iron

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: Participants will consume daily drops of placebo
Study: NCT05743270

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD1 monoclonal antibody
Study: NCT05532501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds